Phibro Animal Health (NASDAQ:PAHC) Updates FY 2026 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) updated its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 2.980-3.100 for the period, compared to the consensus EPS estimate of 3.030. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Wall Street Analysts Forecast Growth

Several research firms have commented on PAHC. Citigroup started coverage on shares of Phibro Animal Health in a report on Wednesday, April 15th. They set a “neutral” rating and a $62.00 price objective for the company. Morgan Stanley set a $49.00 price target on shares of Phibro Animal Health in a research report on Friday, February 6th. Finally, Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 11th. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Phibro Animal Health currently has a consensus rating of “Hold” and an average target price of $42.40.

Phibro Animal Health Trading Up 4.0%

NASDAQ PAHC traded up $2.26 on Wednesday, hitting $58.50. 300,750 shares of the stock were exchanged, compared to its average volume of 273,204. The stock has a fifty day moving average price of $54.07 and a two-hundred day moving average price of $46.48. Phibro Animal Health has a 52-week low of $19.00 and a 52-week high of $60.08. The company has a debt-to-equity ratio of 2.14, a quick ratio of 1.22 and a current ratio of 3.05. The firm has a market capitalization of $2.37 billion, a P/E ratio of 26.00, a P/E/G ratio of 0.84 and a beta of 0.61.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.04. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The company had revenue of $383.54 million during the quarter, compared to analysts’ expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. Research analysts forecast that Phibro Animal Health will post 3.03 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd will be issued a dividend of $0.12 per share. The ex-dividend date is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 0.8%. Phibro Animal Health’s payout ratio is presently 21.33%.

Insider Transactions at Phibro Animal Health

In related news, CEO Jack Bendheim sold 110,842 shares of the business’s stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $48.38, for a total transaction of $5,362,535.96. Following the completion of the transaction, the chief executive officer owned 122,958 shares in the company, valued at $5,948,708.04. The trade was a 47.41% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last three months, insiders sold 281,600 shares of company stock worth $14,334,853. 50.13% of the stock is owned by insiders.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds have recently made changes to their positions in PAHC. iSAM Funds UK Ltd purchased a new stake in shares of Phibro Animal Health in the 3rd quarter worth $61,000. EverSource Wealth Advisors LLC lifted its holdings in shares of Phibro Animal Health by 7,671.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after buying an additional 2,685 shares during the period. C M Bidwell & Associates Ltd. lifted its holdings in shares of Phibro Animal Health by 1,756.5% in the 4th quarter. C M Bidwell & Associates Ltd. now owns 2,135 shares of the company’s stock worth $80,000 after buying an additional 2,020 shares during the period. Advisory Services Network LLC purchased a new stake in shares of Phibro Animal Health in the 3rd quarter worth $96,000. Finally, Tower Research Capital LLC TRC lifted its holdings in shares of Phibro Animal Health by 768.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock worth $118,000 after buying an additional 4,079 shares during the period. 99.34% of the stock is currently owned by hedge funds and other institutional investors.

About Phibro Animal Health

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.